Washington, D.C. Partner David Rosen was quoted in an Inside Health Reform article on July 17, 2013 titled, “FDA Legal Action Holds N.J. Compounder to Manufacturing Standards.” The article discusses a recent consent decree of permanent injunction against a drug compounder that FDA previously flagged mandates the pharmacy follow drug manufacturer standards. Mr. Rosen was quoted saying, “They’re holding them to drug manufacturer-style GMPs.” He also noted that drug companies involved in consent decrees sometimes enter a plan to rehab some of their products, whether it be active pharmaceutical ingredients or ingredients in process, but this must be approved by FDA and there is often a bond to ensure it is carried out.
People
Related News
10 October 2024
In the News
Christopher King Highlights M&A Due Diligence Considerations
Foley & Lardner LLP partner Christopher King's comments on M&A due diligence at the Association of Corporate Counsel's annual meeting were highlighted in the Legal Dive article, "Can this marriage work? Legal tips for corporate M&A."
09 October 2024
In the News
Jason Mehta Weighs in on SEC Settlements, Clinical Research Fraud
Foley & Lardner LLP partner Jason Mehta commented on a recent health care litigation settlement with the U.S. Securities and Exchange Commission in the Clinical Trials Arena article, “Cassava Sciences: Phase III trials storm ahead amid controversy.”
08 October 2024
In the News
John Strom Assesses BIOSECURE ACT – 'Going to be tough to navigate'
Foley & Lardner LLP special counsel John Strom shared insight on the potential impact of the BIOSECURE ACT in the BioSpaces article, "WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow."